- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Legend Biotech Corp (LEGN)
Track today's live Legend Biotech (LEGN) share price, performance and key data on this page with our current NASDAQ:LEGN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Legend Biotech share price on the NASDAQ exchange. Use the dropdown to switch exchange for the LEGN share price, head to our technical summary section, which provides analysis on Legend Biotech share price buy/sell indicators using real-time data (or discuss the Legend Biotech (LEGN) stock price today with other investors in the Legend Biotech NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:LEGN share price (ISIN: US52490G1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Legend Biotech Corp Share Price Today?
The Legend Biotech share price today is 18.57.
What Is the Stock Symbol for Legend Biotech Corp
The stock symbol (or 'ticker') for Legend Biotech Corp is "LEGN."
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:LEGN share price (ISIN: US52490G1022) to enhance your trading decisions with our free investment tools and resources.
What Is the Legend Biotech Corp Share Price Today?
The Legend Biotech share price today is 18.57.
What Is the Stock Symbol for Legend Biotech Corp
The stock symbol (or 'ticker') for Legend Biotech Corp is "LEGN."
What Stock Exchange Does Legend Biotech Corp Trade On?
Legend Biotech Corp is listed and trades on the NASDAQ stock exchange.
Is Legend Biotech Corp a Good Stock to Buy?
Determining whether Legend Biotech (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.52
19.64
52 wk Range
16.24
37.50
Unusual Post-Market activity
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.5219.64
52 wk Range
16.2437.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LEGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
46.50
Upside
+150.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Form 4 Legend Biotech Corp For: 29 September- Investing.com
Form 4 Legend Biotech Corp For: 29 September- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
5 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 46.50
(+150.40% Upside)
Legend Biotech Corp SWOT Analysis
Carvykti's Triumph | Legend Biotech's flagship product Carvykti drives remarkable 74.75% revenue growth, establishing itself as a leading treatment for multiple myeloma |
Financial Fortitude | Explore Legend Biotech's robust liquidity position, with a current ratio of 4.71 and more cash than debt, despite negative EPS |
Pipeline Potential | Delve into Legend Biotech's diverse pipeline, including promising CAR-T therapies for gastric, esophageal, and lung cancers, offering growth beyond Carvykti |
Market Outlook | Analyst price targets range from $71 to $94, with an average of $82.20, reflecting confidence in Legend Biotech's growth prospects and pipeline potential |
Legend Biotech Corp Earnings Call Summary for Q2/2026
- Legend Biotech posted Q2 adjusted EPS of $0.16 vs. $0.07 est., revenue of $387.5M vs. $362.8M est.; first profitable quarter company-wide.
- CARVYKTI sales rose 50% YoY to ~$657M; U.S. sales up 32%, ex-U.S. up 128%; operating margin improved to 15% from negative 9% YoY.
- Management expects adjusted net income profitability through H2 2026; gross margin to reach mid-50% in Q4, targeting 75% long-term.
- Company plans U.S. IND filing for LB2501 in vivo CAR-T by end-2026; CEO search ongoing after leadership transition from Ying Huang.
- Shares rose 5% premarket to $21.70; company holds $965M cash with no long-term debt, plans to settle ~$300M J&J loan in 2026.
Last Updated: 11/08/2026, 14:00
Read Full TranscriptEarnings
Latest Release
11/08/2026
EPS / Forecast
0.16 / 0.07
Revenue / Forecast
387.5M / 362.81M
Compare LEGN to Peers and Sector
Metrics to compare | LEGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLEGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −39.3x | −1.7x | −0.4x | |
PEG Ratio | −0.57 | −0.07 | 0.00 | |
Price/Book | 2.9x | 3.5x | 2.6x | |
Price / LTM Sales | 2.8x | 13.1x | 3.0x | |
Upside (Analyst Target) | 140.7% | 291.6% | 56.4% | |
Fair Value Upside | Unlock | 23.9% | 7.9% | Unlock |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Legend Biotech (NASDAQ: LEGN) Share Price Today?
The Legend Biotech stock price today is 18.57 USD.
What Stock Exchange Does Legend Biotech (LEGN) Trade On?
Legend Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Legend Biotech?
The stock symbol (also called a 'ticker') for Legend Biotech is "LEGN."
What Is the Current Legend Biotech Market Capitalisation?
As of today, Legend Biotech (NASDAQ: LEGN) market cap is 3.60B USD.
What Is Legend Biotech's (LEGN) Earnings Per Share (TTM)?
The Legend Biotech EPS is currently -0.50 (Trailing Twelve Months).
When Is the Next Legend Biotech Earnings Date?
Legend Biotech's next earnings report will be released on 17/11/2026.
Is LEGN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Legend Biotech moving averages and other technical indicators, the daily buy/sell signal for LEGN stock is Neutral.
How Many Times Has Legend Biotech Stock Split?
Legend Biotech has split 0 times. (See the LEGN stock split history page for full effective split date and price information.)
How Many Employees Does Legend Biotech Have?
Legend Biotech has 3200 employees, based on their latest Companies House report.
What is the current trading status of Legend Biotech (NASDAQ: LEGN)?
As of 02/10/2026, Legend Biotech (LEGN) is trading at a share price of 18.57 USD, with a previous close of 19.32 USD. The stock has fluctuated within a day range of 18.52 USD to 19.64 USD, while its 52-week range spans from 16.24 USD to 37.50 USD.
What Is Legend Biotech (LEGN) Price Target According to Analysts?
The average 12-month price target for Legend Biotech is 46.50 USD, with a high estimate of 74 USD and a low estimate of 24 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +150.40% Upside potential.
What Is the LEGN Premarket Price?
LEGN's last pre-market stock price is 19.60 USD. The pre-market share volume is 490.00, and the stock has decreased by 0.28, or 1.45%.
What Is the LEGN After Hours Price?
LEGN's last after hours stock price is 19.61 USD, the stock has decreased by 1.04, or 5.58%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.